A better inhibitory effect was observed when it was used in combination with cisplatin by inhibiting the PI3K/Akt/mTOR signaling pathway, increasing the level of cellular ROS, destroying mitochondrial function, and causing cell energy metabolism disorders in NSCLC. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.